Protagonist Logo. Click to navigate to a home page

TRANSFORMING HEALTHCARE WITH FIRST- AND BEST-IN-CLASS PEPTIDE THERAPEUTICS Research

Using our peptide technology platform, we have developed a pipeline of peptide and small molecule compounds that mimic or inhibit therapeutically relevant protein and protein interactions.

The platform has developed agonists and antagonists of various challenging targets such as cytokines, cytokine receptors, integrin, transmembrane solute transporters, GPCRs, and ion channels. With this technology, Protagonist Therapeutics engineers powerful drug candidates to potentially defeat blood cancers, ulcerative colitis, and other inflammatory diseases.

AREAS OF FOCUS
Arrow icon. Click for more details

Treatments for Rare & Prevalent Diseases

We are creating new peptide-based treatments for blood disorders like polycythemia and inflammatory and immunomodulatory diseases like ulcerative colitis.

TECHNOLOGY
Arrow icon. Click for more details

Groundbreaking Peptide Technology Platform

Through multiple tools, methods, and proprietary know-how, Protagonist engineers first and best-in-class peptide therapeutics to create desired degrees of potency, specificity, solubility, metabolic stability, and manufacturability.

PIPELINE
Arrow icon. Click for more details

Robust Late-Stage Development Pipeline

We are advancing a late stage peptide therapeutic candidate portfolio with significant market potential and a co-development partnership portfolio with Janssen Biotech.

PRODUCT CANDIDATES
Arrow icon. Click for more details

Access to Our Innovation

We are committed to speeding the development of radically improved treatments for polycythemia vera (rusfertide), and inflammatory bowel disease (PN-493).

Share by:
×

Health Equity: Improving Access to Medicines, Ensuring Diverse Representation

Spotlight, Arturo Molina, MD, Chief Medical Officer

Dr. Molina, how are you helping to advance access to medicines?

At Protagonist, we work hard to meet the needs of the patient communities who are relying on us to innovate new and better medicines. Part of our commitment to them includes working to advance our medicines through clinical studies as quickly as possible and ensuring patients can access investigational therapies outside of our clinical trials, which has allowed some patients in critical need to access our therapies for several additional years after trials conclude.

We’re seeing a greater push for better representation in therapeutic innovation across the industry. How is Protagonist supporting diverse and equitable discovery and development?

Protagonist actively works to ensure we have strong patient representation in our clinical studies. We actively seek patients from across urban, suburban, and rural locations, from varying age groups and from among diverse backgrounds to ensure equitable patient representation in our study data.

We’re particularly concerned aging populations are left out of clinical studies, and we’re currently working to recruit older patients into our trials.